GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avivagen Inc (TSXV:VIV) » Definitions » Capex-to-Operating-Cash-Flow

Avivagen (TSXV:VIV) Capex-to-Operating-Cash-Flow : 0.00 (As of Jul. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avivagen Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Avivagen's Capital Expenditure for the three months ended in Jul. 2023 was C$0.00 Mil. Its Cash Flow from Operations for the three months ended in Jul. 2023 was C$0.07 Mil.

Hence, Avivagen's Capex-to-Operating-Cash-Flow for the three months ended in Jul. 2023 was 0.00.


Avivagen Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Avivagen's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avivagen Capex-to-Operating-Cash-Flow Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avivagen's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avivagen's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Avivagen's Capex-to-Operating-Cash-Flow falls into.



Avivagen Capex-to-Operating-Cash-Flow Calculation

Avivagen's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Oct. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -3.117
=N/A

Avivagen's Capex-to-Operating-Cash-Flow for the quarter that ended in Jul. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0.072
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avivagen  (TSXV:VIV) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Avivagen Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Avivagen's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Avivagen (TSXV:VIV) Business Description

Traded in Other Exchanges
Address
100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc is a Canadian-based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal's health defenses. The company's products are based on OxC-beta Technology. Its geographical segments include the Philippines, which is the key revenue driver; Mexico; Thailand; United States; Malaysia; Taiwan; Brazil; and others.

Avivagen (TSXV:VIV) Headlines

From GuruFocus

1Q20 Results: Telefônica Brasil S.A.

By PRNewswire PRNewswire 05-06-2020

4Q21 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 02-23-2022

2Q20 Results: Telefônica Brasil S.A.

By PRNewswire PRNewswire 07-29-2020

1Q22 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 05-30-2022

3Q20 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 10-28-2020

2Q23 Results: Telef�nica Brasil S.A.

By PRNewswire 07-25-2023

1Q22 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 06-29-2022

4Q22 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 02-15-2023

2Q21 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 07-27-2021